Olema stock soared Tuesday after Roche reported strong clinical results for its breast cancer drug. An Oppenheimer analyst sees significant further upside in OLMA shares to $45.

The partnership will expedite the availability of Freenome's tests in markets outside the U.S, according to the company.

Olema Pharmaceuticals (OLMA) surges after Roche's breast cancer data, but caution is urged as key clinical results are ...

Roche recently announced positive Phase 3 trial results for its breast cancer therapy, giredestrant, which operates through a mechanism that directly parallels Olema Pharmaceuticals’ lead candidate, ...

Roche AG’s Genentech unit landed another clinical victory with giredestrant that provided a major stock boost for competitor Olema Pharmaceuticals Inc. Made public were positive phase III data from ...

According to DataM Intelligence AUSTIN, Texas and TOKYO, Nov. 18, 2025 /PRNewswire/ -- DataM Intelligence announces the latest insights into the rapidly transforming Oncology Molecular Diagnostics ...

FDA approves Poherdy, the first interchangeable biosimilar for Perjeta, enhancing competition in HER2-positive breast cancer ...

Roche claimed the results make its drug giredestrant the first of its kind, a so-called oral SERD, to show a benefit in the ...

OLMA stock surged 197% after Roche’s SERD breakthrough, signaling investor conviction in the future of ER-positive breast ...

(OLMA) more than doubled Tuesday morning on the heels of Roche announcing positive results from its late-stage trial in ...

Roche posts positive phase 3 results for giredestrant in early breast cancer, showing improved disease-free survival and a ...